Proteinase 3-ANCA vasculitis versus myeloperoxidase- ANCA vasculitis

Journal of the American Society of Nephrology

Volumn 26, Issue 10, 2015, Pages 2314-2327

  Hilhorst, Marc ^a   Van Paassen, Pieter ^a   Tervaert, Jan Willem Cohen ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DPB1 ANTIGEN; HLA DQ ANTIGEN; IMMUNOGLOBULIN; METHOTREXATE; MIZORIBINE; MYCOPHENOLATE MOFETIL; MYELOBLASTIN; MYELOPEROXIDASE; RITUXIMAB; PEROXIDASE;

ALLELE; ANCA ASSOCIATED VASCULITIS; ASIA; AUSTRALIA; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE MODEL; EUROPE; FIBROSIS; GENETIC ANALYSIS; GEOGRAPHIC DISTRIBUTION; GRANULOMATOSIS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; INCIDENCE; KIDNEY BIOPSY; KIDNEY DISEASE; MICROSCOPY; NEW ZEALAND; NONHUMAN; ONSET AGE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SEROTYPE; SKIN DEFECT; SMALL VESSEL VASCULITIS; SURVIVAL; ANIMAL; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; COMPARATIVE STUDY; ENZYMOLOGY; METABOLISM;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; DISEASE MODELS, ANIMAL; HUMANS; MYELOBLASTIN; PEROXIDASE;

EID: 84942885282     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014090903     Document Type: Review

References (176)

1. Cohen Tervaert JW, Damoiseaux J. Fifty years of antineutrophil cytoplasmic antibodies (ANCA) testing: do we need to revise the international consensus statement on testing and reporting on ANCA? APMIS Suppl 127: 55-59, 2009.
2. Davies DJ, Moran JE, Niall JF, Ryan GB: Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 285: 606, 1982.
3. van der Woude FJ, RasmussenN, Lobatto S, Wiik A, PerminH, van Es LA, van der Giessen M, van der Hem GK, The TH: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1: 425-429, 1985.
4. Klinger H: Grenzformen der Periarteriitis nodosa. Frankf Z Pathol 42: 455-480, 1931.
5. Wegener F: Über eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr Pathol Anat 102: 36-68, 1939.
6. Falk RJ, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.N Engl J Med 318: 1651-1657, 1988.
7. Tervaert JW, Goldschmeding R, Elema JD, von dem Borne AEGK, Kallenberg CG: Antimyeloperoxidase antibodies in the Churg- Strauss syndrome. Thorax 46: 70-71, 1991.
8. Cohen Tervaert JW, Damoiseaux J: Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? Clin Rev Allergy Immunol 43: 211-219, 2012.
9. Kallenberg CG, Mulder AH, Tervaert JW: Antineutrophil cytoplasmic antibodies: a stillgrowing class of autoantibodies in inflammatory disorders. Am J Med 93: 675-682, 1992.
10. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Lüdemann J, Rasmussen N, Sinico RA, Wiik A, van der Woude FJ: Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 53: 743-753, 1998.
11. Tervaert JW, Goldschmeding R, Elema JD, Limburg PC, van der Giessen M, Huitema MG, Koolen MI, Hené RJ, The TH, van der Hem GK, et al: Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 33: 1264-1272, 1990.
12. Goldschmeding R, Tervaert JW, Gans RO, Dolman KM, van den Ende ME, Kuizinga MC, Kallenberg CG, von dem Borne AE: Different immunological specificities and disease associations of c-ANCA and p- ANCA. Neth J Med 36: 114-116, 1990.
13. Tervaert JW, Goldschmeding R, Elema JD, van der Giessen M, Huitema MG, van der Hem GK, The TH, von dem Borne AE, Kallenberg CG: Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 37: 799- 806, 1990.
14. Tervaert JW, Elema JD, Kallenberg CG: Clinical and histopathological association of 29kD-ANCA and MPO-ANCA. APMIS Suppl 19: 35, 1990.
15. Tervaert JW, Limburg PC, Elema JD, Huitema MG, Horst G, The TH, Kallenberg CG: Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsyproven necrotizing arteritis. Am JMed 91: 59-66, 1991.
16. Geffriaud-Ricouard C, Noël LH, Chauveau D, Houhou S, Grünfeld JP, Lesavre P: Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 39: 125-136, 1993.
17. Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ, Tervaert JW: Antiproteinase 3- And antimyeloperoxidase- Associated vasculitis. Kidney Int 57: 2195-2206, 2000.
18. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924-926, 2008.
19. Knight A, Ekbom A, Brandt L, Askling J: Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001.J Rheumatol 33: 2060-2063, 2006.
20. Scott DG, Watts RA: Epidemiology and clinical features of systemic vasculitis. Clin Exp Nephrol 17: 607-610, 2013.
21. Hilhorst M, Wilde B, van Breda Vriesman P, van Paassen P, Cohen Tervaert JW; Limburg Renal Registry: Estimating renal survival using the ANCA-associated GN classification. J Am Soc Nephrol 24: 1371-1375, 2013.
22. Watts RA, Lane SE, Bentham G, Scott DG: Epidemiology of systemic vasculitis: a tenyear study in the United Kingdom. Arthritis Rheum 43: 414-419, 2000.
23. González-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J: The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 49: 388-393, 2003.
24. Fujimoto S, Watts R, Kobayashi S, Suzuki K, Jayne D, Scott D, et al Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology 50: 1916-1920, 2011.
25. Chen M, Yu F, Zhang Y, Zhao MH: Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore) 87: 203-209, 2008.
26. Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DG: Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 60: 170-172, 2001.
27. Ntatsaki E, Watts RA, Scott DG: Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am 36: 447-461, 2010.
28. Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M: Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg- Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 46: 1329-1337, 2007.
29. O'Donnell JL, Stevanovic VR, Frampton C, Stamp LK, Chapman PT: Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern Med J 37: 242-246, 2007.
30. Gibson A, Stamp LK, Chapman PT, O'Donnell JL: The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology (Oxford) 45: 624-628, 2006.
31. Koldingsnes W, Nossent H: Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 43: 2481-2487, 2000.
32. Ormerod AS, Cook MC: Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J 38: 816-823, 2008.
33. Monach PA, Merkel PA: Genetics of vasculitis. Curr Opin Rheumatol 22: 157-163, 2010.
34. Slot MC, Sokolowska MG, Savelkouls KG, Janssen RG, Damoiseaux JG, Tervaert JW: Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis. Clin Immunol 128: 39-45, 2008.
35. Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, Hellmich B, Gross WL, Epplen JT: The PTPN22 620Wallele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 52: 4039-4043, 2005.
36. DijstelbloemHM, Scheepers RH, OostWW, Stegeman CA, van der Pol WL, Sluiter WJ, Kallenberg CG, van de Winkel JG, Tervaert JW: Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum 42: 1823- 1827, 1999.
37. Stassen PM, Cohen-Tervaert JW, Lems SP, Hepkema BG, Kallenberg CG, Stegeman CA: HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. Rheumatology (Oxford) 48: 622-625, 2009.
38. Xie G, Roshandel D, Sherva R, Monach PA, Lu EY, Kung T, Carrington K, Zhang SS, Pulit SL, Ripke S, Carette S, Dellaripa PF, Edberg JC, Hoffman GS, Khalidi N, Langford CA, Mahr AD, St Clair EW, Seo P, Specks U, Spiera RF, Stone JH, Ytterberg SR, Raychaudhuri S, de Bakker PI, Farrer LA, Amos CI, Merkel PA, Siminovitch KA: Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1∗04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum 65: 2457-2468, 2013.
39. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hrušková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesar V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, ClaytonDG, Smith KG:Genetically distinct subsets within ANCA-associated vasculitis.N Engl J Med 367: 214-223, 2012.
40. Gencik M, Meller S, Borgmann S, Fricke H: Proteinase 3 gene polymorphisms and Wegener's granulomatosis. Kidney Int 58: 2473-2477, 2000.
41. Esnault VL, Testa A, Audrain M, Rogé C, Hamidou M, Barrier JH, Sesboüé R, Martin JP, Lesavre P: Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 43: 1329-1332, 1993.
42. Wieczorek S, Hoffjan S, Chan A, Rey L, Harper L, Fricke H, Holle JU, Gross WL, Epplen JT, Lamprecht P: Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. Genes Immun 10: 591- 595, 2009.
43. Wieczorek S, Holle J, Cohen Tervaert JW, Harper L, Moosig F, Gross WL, et al: The SEM6A6 locus is not associated with GPA or other forms of ANCA associated vasculitides in Europeans. Arthritis Rheum 66: 1400-1401, 2014.
44. Cao Y, Schmitz JL, Yang J, Hogan SL, Bunch D, Hu Y, Jennette CE, Berg EA, Arnett FC Jr, Jennette JC, Falk RJ, Preston GA: DRB1∗15 allele is a risk factor for PR3-ANCA disease in African Americans. J AmSocNephrol 22: 1161-1167, 2011.
45. Gatenby PA, Lucas RM, Engelsen O, Ponsonby AL, Clements M: Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation? Arthritis Rheum 61: 1417-1424, 2009.
46. de Lind van Wijngaarden RA, van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JW, Mahr AD, Niles JL, de Heer E, Bruijn JA, Bajema IM: Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol 3: 237-252, 2008.
47. Cohen Tervaert JW: Silicon exposure and vasculitis. In: Encyclopedia of metalloproteins, edited by Uversky V, Kretsinger R, Permyakov E, Berlin, Springer Science, 2012, pp 1983-1988.
48. Lee S, Hayashi H, Maeda M, Chen Y, Matsuzaki H, Takei-Kumagai N, Nishimura Y, Fujimoto W, Otsuki T: Environmental factors producing autoimmune dysregulation- chronic activation of T cells caused by silica exposure. Immunobiology 217: 743-748, 2012.
49. Wilde B, Hua F, Dolff S, Jun C, Cai X, Specker C, Feldkamp T, Kribben A, Cohen Tervaert JW, Witzke O: Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. Rheumatology (Oxford) 51: 1188-1197, 2012.
50. Rocha-Parise M, Santos LM, Damoiseaux JG, Bagatin E, Lido AV, Torello CO, Cohen Tervaert JW, Queiroz ML: Lymphocyte activation in silica-exposed workers. Int J Hyg Environ Health 217: 586-591, 2014.
51. Yashiro M, Muso E, Itoh-Ihara T, Oyama A, Hashimoto K, Kawamura T, Ono T, Sasayama S: Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis 35: 889-895, 2000.
52. Hilhorst M, Wilde B, van Paassen P, Winkens B, van Breda Vriesman P, Cohen Tervaert JW; Limburg Renal Registry: Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 28: 373-379, 2013.
53. Gross WL, Trabandt A, Reinhold-Keller E: Diagnosis and evaluation of vasculitis. Rheumatology (Oxford) 39: 245-252, 2000.
54. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120: 12-17, 1994.
55. Popa ER, Tervaert JW: The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med 42: 771- 780, 2003.
56. Belizna CC, Hamidou MA, Levesque H, Guillevin L, Shoenfeld Y: Infection and vasculitis. Rheumatology (Oxford) 48: 475- 482, 2009.
57. Miranda-Filloy JA, Veiga JA, Juarez Y, Gonzalez-Juanatey C, Gonzalez-Gay MA, Garcia-Porrua C: Microscopic polyangiitis following recurrent Staphylococcus aureus bacteremia and infectious endocarditis. Clin Exp Rheumatol 24: 705-706, 2006.
58. Hellmich B, Ehren M, Lindstaedt M, Meyer M, Pfohl M, Schatz H: Anti-MPO-ANCApositive microscopic polyangiitis following subacute bacterial endocarditis. Clin Rheumatol 20: 441-443, 2001.
59. Lawyer C, Henkle J, Bakir H: Nasal carriage of staphylococcal infection in Wegener granulomatosis. Ann Intern Med 121: 74- 75, 1994.
60. Preston GA, Pendergraft WF 3rd, Falk RJ: New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity. Curr Opin Nephrol Hypertens 14: 217-222, 2005.
61. Kain R, Matsui K, Exner M, Binder S, Schaffner G, Sommer EM, Kerjaschki D: A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-LAMP-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 181: 585-597, 1995.
62. Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, Davidovits A, Raab I, Jahn R, Ashour O, Spitzauer S, Sunder-Plassmann G, Fukuda M, Klemm P, Rees AJ, Kerjaschki D: Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 14: 1088-1096, 2008.
63. Falk RJ, Terrell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 87: 4115-4119, 1990.
64. Schreiber A, Luft FC, Kettritz R: Membrane proteinase 3 expression and ANCAinduced neutrophil activation. Kidney Int 65: 2172-2183, 2004.
65. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL: Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 95: 244- 250, 1994.
66. Yang JJ, Pendergraft WF, Alcorta DA, Nachman PH, Hogan SL, Thomas RP, Sullivan P, Jennette JC, Falk RJ, Preston GA: Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol 15: 2103-2114, 2004.
67. Ciavatta DJ, Yang J, Preston GA, Badhwar AK, XiaoH, Hewins P, Nester CM, Pendergraft WF 3rd, Magnuson TR, Jennette JC, Falk RJ: Epigenetic basis for aberrant upregulation of autoantigen genes in humanswith ANCA vasculitis. J Clin Invest 120: 3209- 3219, 2010.
68. Ben-Smith A, Dove SK, Martin A, Wakelam MJ, Savage CO: Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcgamma receptor ligation. Blood 98: 1448-1455, 2001.
69. Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG: Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 13: 2232-2238, 2002.
70. Savage CO, Gaskin G, Pusey CD, Pearson JD: Anti-neutrophil cytoplasm antibodies can recognize vascular endothelial cellbound anti-neutrophil cytoplasm antibodyassociated autoantigens. Exp Nephrol 1: 190-195, 1993.
71. Yang JJ, Preston GA, Pendergraft WF, Segelmark M, Heeringa P, Hogan SL, Jennette JC, Falk RJ: Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants. Am J Pathol 158: 581- 592, 2001.
72. Le Roux S, Pepper RJ, Dufay A, Néel M, Meffray E, Lamandé N, Rimbert M, Josien R, Hamidou M, Hourmant M, Cook HT, Charreau B, Larger E, Salama AD, Fakhouri F: Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 23: 155-164, 2012.
73. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE: Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J ExpMed 203: 2165-2175, 2006.
74. Kettritz R: With complements from ANCA mice. J Am Soc Nephrol 25: 207-209, 2014.
75. Coughlan AM, Freeley SJ, Robson MG: Animal models of anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Immunol 169: 229-237, 2012.
76. Brouwer E, Huitema MG, Klok PA, de Weerd H, Tervaert JW, Weening JJ, Kallenberg CG: Antimyeloperoxidaseassociated proliferative glomerulonephritis: an animal model. J Exp Med 177: 905-914, 1993.
77. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955-963, 2002.
78. Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P: Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factoralpha. Am J Pathol 167: 47-58, 2005.
79. Little MA, Smyth CL, Yadav R, Ambrose L, Cook HT, Nourshargh S, Pusey CD: Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocytemicrovascular interactions in vivo. Blood 106: 2050-2058, 2005.
80. van der Geld YM, Hellmark T, Selga D, Heeringa P, Huitema MG, Limburg PC, Kallenberg CG: Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis 66: 1679- 1682, 2007.
81. Primo VC, Marusic S, Franklin CC, Goldmann WH, Achaval CG, Smith RN, Arnaout MA, Nikolic B: Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis. Clin Exp Immunol 159: 327-337, 2010.
82. Little MA, Al-Ani B, Ren S, Al-Nuaimi H, Leite M Jr, Alpers CE, Savage CO, Duffield JS: Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS ONE 7: e28626, 2012.
83. Korkmaz B, Kuhl A, Bayat B, Santoso S, Jenne DE: A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. J Biol Chem 283: 35976-35982, 2008.
84. Pfister H, Ollert M, Fröhlich LF, Quintanilla- Martinez L, Colby TV, Specks U, Jenne DE: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104: 1411-1418, 2004.
85. Holl-Ulrich K: L18. Granuloma formation in granulomatosis with polyangiitis. Presse Med 42: 555-558, 2013.
86. Park JK, Askin F, Giles JT, Halushka MK, Rosen A, Levine SM: Increased generation of TRAP expressing multinucleated giant cells in patients with granulomatosis with polyangiitis. PLoS ONE 7: e42659, 2012.
87. Hilhorst M, Shirai T, Berry GJ, Goronzy J, Weyand C: T cell-macrophage interactions and granuloma formation in vasculitis. Front Immunol 5: 432, 2014.
88. Fienberg R, Mark EJ, Goodman M, McCluskey RT, Niles JL: Correlation of antineutrophil cytoplasmic antibodies with the extrarenal histopathology ofWegener's (pathergic) granulomatosis and related forms of vasculitis. Hum Pathol 24: 160- 168, 1993.
89. Falk RJ, Jennette JC: ANCA small-vessel vasculitis. J Am Soc Nephrol 8: 314-322, 1997.
90. Bajema IM, Hagen EC, Hansen BE, Hermans J, Noël LH, Waldherr R, Ferrario F, van der Woude FJ, Bruijn JA: The renal histopathology in systemic vasculitis: an international survey study of inter- And intra-observer agreement. Nephrol Dial Transplant 11: 1989-1995, 1996.
91. Haas M, Rastaldi MP, Fervenza FC: Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney Int 85: 779-793, 2014.
92. Franssen CF, Gans RO, Arends B, Hageluken C, ter Wee PM, Gerlag PG, Hoorntje SJ: Differences between antimyeloperoxidase- And anti-proteinase 3- Associated renal disease. Kidney Int 47: 193-199, 1995.
93. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC; European Vasculitis Study Group (EUVAS): Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61: 80-89, 2002.
94. Franssen CF, Stegeman CA, Oost-Kort WW, Kallenberg CG, Limburg PC, Tiebosch A, De Jong PE, Tervaert JW: Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 9: 1915-1923, 1998.
95. Hauer HA, Bajema IM, Hagen EC, Noël LH, Ferrario F, Waldherr R, van Houwelingen HC, Lesavre P, Sinico RA, van der Woude F, Gaskin G, Verburgh CA, de Heer E, Bruijn JA: Long-term renal injury in ANCAassociated vasculitis: an analysis of 31 patients with follow-up biopsies. Nephrol Dial Transplant 17: 587-596, 2002.
96. Rihova Z, Jancova E, Merta M, Rysava R, Reiterova J, Zabka J, Tesar V: Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press Res 28: 144-152, 2005.
97. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, RasmussenN, Noël LH, Ferrario F, Waldherr R, Hagen EC, Bruijn JA, Bajema IM: Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 17: 2264-2274, 2006.
98. de Joode AA, Sanders JS, Stegeman CA: Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 8: 1709-1717, 2013.
99. Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, Ito T, Nureki S, Kumamoto T: Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med 107: 608-615, 2013.
100. Arulkumaran N, Periselneris N, Gaskin G, Strickland N, Ind PW, Pusey CD, Salama AD: Interstitial lung disease and ANCAassociated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 50: 2035-2043, 2011.
101. Homma S, Matsushita H, Nakata K: Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology 9: 190-196, 2004.
102. Chen M, Yu F, Zhang Y, Zou WZ, Zhao MH, Wang HY: Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int 68: 2225-2229, 2005.
103. Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S:Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with antiproteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 244: 209- 216, 1998.
104. Guilpain P, Servettaz A, Goulvestre C, Barrieu S, Borderie D, Chéreau C, Kavian N, Pagnoux C, Guillevin L, Weill B, Mouthon L, Batteux F: Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum 56: 2455-2463, 2007.
105. Haas M, Eustace JA: Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int 65: 2145-2152, 2004.
106. Neumann I, Regele H, Kain R, Birck R, Meisl FT: Glomerular immune deposits are associatedwith increased proteinuria in patients with ANCA-associated crescentic nephritis. Nephrol Dial Transplant 18: 524-531, 2003.
107. van Paassen P, van Breda Vriesman PJ, van Rie H, Tervaert JW: Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 66: 909-913, 2004.
108. Chen M, Daha MR, Kallenberg CG: The complement system in systemic autoimmune disease. J Autoimmun 34: J276- J286, 2010.
109. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R: C5a receptor mediates neutrophil activation and ANCAinduced glomerulonephritis. J Am Soc Nephrol 20: 289-298, 2009.
110. Vogt W: Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes. Immunobiology 195: 334-346, 1996.
111. Westman KW, Bygren PG, Olsson H, RanstamJ, Wieslander J: Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9: 842-852, 1998.
112. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C, Adu D: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87: 671-678, 1994.
113. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA: Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68: 1827-1832, 2009.
114. Falk RJ, Hogan S, Carey TS, Jennette JC; The Glomerular Disease Collaborative Network: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 113: 656-663, 1990.
115. Homma S, Suzuki A, Sato K: Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist. Clin Exp Nephrol 17: 667-671, 2013.
116. Pesci A, Pavone L, Buzio C, Manganelli P: Respiratory system involvement in ANCAassociated systemic vasculitides. Sarcoidosis Vasc Diffuse Lung Dis 22[Suppl 1]: S40-S48, 2005.
117. Hrusková Z, Casian AL, Konopasek P, Svobodova B, Frausova D, Lanska V, Tesar V, Jayne DR: Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand J Rheumatol 42: 211-214, 2013.
118. West S, Arulkumaran N, Ind PW, Pusey CD: Diffuse alveolar haemorrhage in ANCAassociated vasculitis. Intern Med 52: 5-13, 2013.
119. Martinez Del Pero M, Sivasothy P: Vasculitis of the upper and lower airway. Best Pract Res Clin Rheumatol 23: 403-417, 2009.
120. Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Höglund P, Merkel PA, Pagnoux C, Rasmussen N, Westman K, Jayne DR; French Vasculitis StudyGroup (FVSG) and the European Vasculitis Society (EUVAS): Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibodyassociated vasculitis: a cluster analysis. Ann Rheum Dis 72: 1003-1010, 2013.
121. Suppiah R, Hadden RD, Batra R, Arden NK, Collins MP, Guillevin L, Jayne DR, Luqmani RA; European Vasculitis Study Group: Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology (Oxford) 50: 2214-2222, 2011.
122. Magnus T, Melms A, Kötter I, Holle JU: [Neurological manifestations of vasculitis and primary central nervous system vasculitis]. Z Rheumatol 71: 551-563, 2012.
123. Wolf J, Schmitt V, Palm F, Grau AJ, Bergner R: Peripheral neuropathy as initial manifestation of primary systemic vasculitides. J Neurol 260: 1061-1070, 2013.
124. Cattaneo L, Chierici E, Pavone L, Grasselli C, Manganelli P, Buzio C, Pavesi G: Peripheral neuropathy in Wegener's granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry 78: 1119-1123, 2007.
125. Chen KR: Skin involvement in ANCAassociated vasculitis. Clin Exp Nephrol 17: 676-682, 2013.
126. Schmidt J, Pulido JS, Matteson EL: Ocular manifestations of systemic disease: antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Ophthalmol 22: 489- 495, 2011.
127. Rothschild PR, Pagnoux C, Seror R, Brézin AP, Delair E, Guillevin L: Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Semin Arthritis Rheum 42: 507-514, 2013.
128. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 51: 269-273, 2004.
129. Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D; European Vasculitis Study Group: Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64: 542-548, 2012.
130. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ: Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64: 3452-3462, 2012.
131. Kemna M, Damoiseaux J, Austen J, Winkens B, Peters J, Van Paassen P, Cohen Tervaert JW: ANCA as a Predictor of Relapse: Useful in Patients with Renal Involvement But Not in Patients with Nonrenal Disease. J Am Soc Nephrol 26: 537-542, 2014.
132. Day CJ, Howie AJ, Nightingale P, Shabir S, Adu D, Savage CO, Hewins P: Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine. Am J Kidney Dis 55: 250-258, 2010.
133. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR; Pan-Thames Renal Research Group:Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41: 776-784, 2003.
134. Eriksson P, Jacobsson L, Lindell A, Nilsson JA, Skogh T: Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 265: 496-506, 2009.
135. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH; RAVE-ITN Research Group: Efficacy of remission-induction regimens for ANCA-associated vasculitis.N Engl J Med 369: 417-427, 2013.
136. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H, Luqmani RA; European Vasculitis Study Group (EUVAS): Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 67: 1004-1010, 2008.
137. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC; European Vasculitis Study Group (EUVAS): Determinants of outcome in ANCAassociated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 62: 1732-1742, 2002.
138. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD: ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 19: 1403- 1411, 2004.
139. Kapitsinou PP, Ioannidis JP, Boletis JN, Sotsiou F, Nakopoulou L, Daphnis E, Moutsopoulos HM: Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. Am J Kidney Dis 41: 29-37, 2003.
140. Sriskandarajah S, Aasarød K, Skrede S, Knoop T, Reisæter A, Bjørneklett R. Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies [published online ahead of print February 17, 2015]. Nephrol Dial Transplant 10.1093/ndt/gfv008.
141. Tanna A, Guarino L, Tam F, Rodriguez- Cubillo B, Levy J, Cairns TD, Griffith M, Tarzi RM, Caplin B, Salama AD, Cook T, Pusey CD: Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors [published online ahead of print July 12, 2014]. Nephrol Dial Transplant 10.1093/ndt/gfu237.
142. Mohammad AJ, Segelmark M: A populationbased study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCAassociated nephritis. J Rheumatol 41: 1366- 1373, 2014.
143. Slot MC, Tervaert JW, Franssen CF, Stegeman CA: Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 63: 670-677, 2003.
144. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, Jayne D, Harper L; European Vasculitis Study (EUVAS) Group: Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69: 1036-1043, 2010.
145. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K; European Vasculitis Study Group: Long-term patient survival in ANCAassociated vasculitis. Ann Rheum Dis 70: 488-494, 2011.
146. Suppiah R, Judge A, Batra R, Flossmann O, Harper L, Höglund P, Javaid MK, Jayne D, Mukhtyar C, Westman K, Davis JC Jr, HoffmanGS, McCuneWJ, Merkel PA, St Clair EW, Seo P, Spiera R, Stone JH, Luqmani R: A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis andmicroscopic polyangiitis. Arthritis Care Res (Hoboken) 63: 588-596, 2011.
147. Cohen Tervaert JW: Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol 27: 33-44, 2013.
148. Merkel PA, Lo GH, Holbrook JT, Tibbs AK, AllenNB, Davis JC Jr, HoffmanGS, McCune WJ, St Clair EW, Specks U, Spiera R, Petri M, Stone JH; Wegener's Granulomatosis Etanercept Trial Research Group: Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (We- CLOT) Study. Ann Intern Med 142: 620- 626, 2005.
149. Stassen PM, Derks RP, Kallenberg CG, Stegeman CA: Venous thromboembolism in ANCA-associated vasculitis-incidence and risk factors. Rheumatology (Oxford) 47: 530-534, 2008.
150. Hilhorst M, Winckers K, Wilde B, van Oerle R, ten Cate H, Tervaert JW: Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol 40: 2042-2046, 2013.
151. Harper L: L42. Morbidity in patients with ANCA-associated vasculitis. Presse Med 42: 612-616, 2013.
152. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, SegelmarkM, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211-220, 2010.
153. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, WeitzenkampD, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232, 2010.
154. Guillevin L, Pagnoux C, Karras A, Khouatra C, AumaÎtre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L; French Vasculitis Study Group: Rituximab versus azathioprine for maintenance in ANCAassociated vasculitis. N Engl J Med 371: 1771-1780, 2014.
155. Wilde B, van Paassen P, Witzke O, Tervaert JW: New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 79: 599-612, 2011.
156. Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, Ytterberg SR, Hoffman GS, Krischer JP, Merkel PA; Vasculitis Clinical Research Consortium: An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 73: 1376-1379, 2014.
157. de Joode AA, Sanders JS, Smid WM, Stegeman CA: Plasmapheresis rescue therapy in progressive systemic ANCAassociated vasculitis: single-center results of stepwise escalation of immunosuppression. J Clin Apher 29: 266-272, 2014.
158. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, Lockwood CM: Intravenous immunoglobulin for ANCAassociated systemic vasculitis with persistent disease activity. QJM 93: 433-439, 2000.
159. Flossmann O, Baslund B, Bruchfeld A, Tervaert JW, Hall C, Heinzel P, Hellmich B, Luqmani RA, Nemoto K, Tesar V, Jayne DR: Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 68: 1125-1130, 2009.
160. Stassen PM, Tervaert JW, Stegeman CA: Induction of remission in active antineutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 66: 798-802, 2007.
161. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory antineutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH- 1H). Ann Rheum Dis 67: 1322-1327, 2008.
162. Nishioka Y, Horita Y, Tadokoro M, Taura K, Suyama N, Miyazaki M, Harada T, Kohno S: Mizoribine induces remission of relapsed ANCA-associated renal vasculitis. Nephrol Dial Transplant 21: 1087-1088, 2006.
163. Huugen D, van Esch A, Xiao H, Peutz- Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P: Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 71: 646-654, 2007.
164. Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC: C5a receptor (CD88) blockade protects againstMPO-ANCAGN. J AmSoc Nephrol 25: 225-231, 2014.
165. Springer J, Nutter B, Langford CA, Hoffman GS, Villa-Forte A: Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore) 93: 82-90, 2014.
166. Furuta S, Jayne D: Emerging therapies in antineutrophil cytoplasm antibodyassociated vasculitis. Curr Opin Rheumatol 26: 1-6, 2014.
167. Jennette JC, Falk RJ, Bacon PA, BasuN, Cid MC, Ferrario F, Flores-Suarez LF, GrossWL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA: 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65: 1-11, 2013.
168. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36-44, 2003.
169. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, GrossWL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO; EUVAS (European Vasculitis Study Group): Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150: 670-680, 2009.
170. Hiemstra TF, Walsh M, Mahr A, Savage CO, deGroot K, Harper L, Hauser T, Neumann I, Tesar V, Wissing KM, Pagnoux C, Schmitt W, Jayne DR; European Vasculitis Study Group (EUVAS): Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibodyassociated vasculitis: a randomized controlled trial. JAMA 304: 2381-2388, 2010.
171. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD; European Vasculitis Study Group: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180-2188, 2007.
172. Metzler C, Miehle N, Manger K, Iking- Konert C, de Groot K, Hellmich B, Gross WL, Reinhold-Keller E; German Network of Rheumatic Diseases: Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46: 1087-1091, 2007.
173. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461-2469, 2005.
174. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L; French Vasculitis Study Group: Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359: 2790-2803, 2008.
175. Wegener'sGranulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351-361, 2005.
176. Silva F, Specks U, Kalra S, HoganMC, Leung N, Sethi S, Fervenza FC: Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement-A prospective, open-label pilot trial. Clin J Am Soc Nephrol 5: 445-453, 2010.